Novartis-backed Inflazome raises $46M for their clinical challenge to prove NLRP3 is a great anti-inflammatory target
The big CANTOS study may not have produced the blockbuster approval that Novartis had been promising in cardio, but its success in the IL-1 beta pathway has helped inspire a slate of startups that are moving upstream to what’s become a hot field in NLRP3 inhibition.
Today’s story centers on Inflazome, which describes itself as one of the pioneers in NLRP3. The biotech has raised $46 million for its Series B round to shift out of preclinical work and head straight into the clinic next year, with plans to tee up a safety study followed by a foray into an orphan CNS condition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
